Biomarin Pharmaceutical Inc. is paying $14.50 per share to acquire rare disease drug developer Amicus Therapeutics Inc. in an all-cash transaction valued at about $4.8 billion. The deal will bolster ...

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to ...

Amira Therapeutics SL has announced new preclinical findings for its lead compound AMI-463, which is being developed primarily for rhabdomyosarcoma, the most common soft tissue sarcoma in children.

The Trump administration has made known that it intends to foster rapid adoption of AI, starting with a repeal of an executive order (EO) issued by the Biden administration. Now, the White House has ...

Ehrlich Biotechnology Co. Ltd. has described antibody-drug conjugates comprising an antibody targeting EGFR (HER1; erbB1) covalently linked to a camptothecin derivative through a linker reported to be ...

Aché Laboratórios Farmacêuticos SA has synthesized compounds acting as β2-adrenoceptor (ADRB2) agonists and muscarinic M3 receptor antagonists reported to be useful for the treatment of asthma, ...

During aging, hematopoietic stem cells (HSCs) undergo functional decline affecting their ability to regenerate the hematopoietic system and support lymphoid cell production. This functional decline ...

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed RAC-α serine/threonine-protein kinase (AKT1; PKB α) (Glu17Lys mutant) inhibitors reported to be useful for the treatment of leukemia.

Neok Bio Inc. made a moderate splash by emerging from stealth mode in November with a $75 million series A financing led by Abl Bio Inc. – and one aspect of its drug development is gaining momentum in ...

Viatris Inc. has announced FDA clearance of its IND application for MR-146, an Enriched Tear Film (ETF) AAV gene therapy candidate for the treatment of neurotrophic keratopathy. The company plans to ...

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accendra, Biotronik, Curasight, Envue, Medipost, Owens & Minor, Soin Neuroscience, Teikoku ...

Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per share in an all-cash transaction, ...